Co-regulation of Gremlin and Notch signalling in diabetic nephropathy David W. Walsh, Sarah A. Roxburgh, Paul Mcgettigan, Celine C. Berthier, Desmond G. Higgins, Matthias Kretzler, Clemens D. Cohen, Sergio Mezzano, Derek P. Brazil, Finian Martin
To cite this version:
David W. Walsh, Sarah A. Roxburgh, Paul Mcgettigan, Celine C. Berthier, Desmond G. Higgins, et al.. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochimica et Biophysica Acta - Molecular Basis of Disease, Elsevier, 2008, 1782 (1), pp.10. 10.1016/j.bbadis.2007.09.005. hal-00501552
HAL Id: hal-00501552 https://hal.archives-ouvertes.fr/hal-00501552 Submitted on 12 Jul 2010
HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés.
ÔØ ÅÒÙ×Ö ÔØ
Co-regulation of Gremlin and Notch signalling in diabetic nephropathy
David W. Walsh, Sarah A. Roxburgh, Paul McGettigan, Celine C. Berthier, Desmond G. Higgins, Matthias Kretzler, Clemens D. Cohen, Sergio Mezzano, Derek P. Brazil, Finian Martin
PII: S0925-4439(07)00191-3 DOI: doi: 10.1016/j.bbadis.2007.09.005 Reference: BBADIS 62755
To appear in: BBA - Molecular Basis of Disease
Received date: 26 June 2007 Revised date: 4 September 2007 Accepted date: 28 September 2007
Please cite this article as: David W. Walsh, Sarah A. Roxburgh, Paul McGettigan, Celine C. Berthier, Desmond G. Higgins, Matthias Kretzler, Clemens D. Cohen, Sergio Mezzano, Derek P. Brazil, Finian Martin, Co-regulation of Gremlin and Notch signalling in diabetic nephropathy, BBA - Molecular Basis of Disease (2007), doi: 10.1016/j.bbadis.2007.09.005
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT
Co-regulation of Gremlin and Notch signalling in diabetic
nephropathy
David W. Walsh1*, Sarah A. Roxburgh2, 3*, Paul McGettigan2, Celine C. Berthier4,
Desmond G. Higgins2, Matthias Kretzler4, Clemens D. Cohen5, Sergio Mezzano6,
Derek P. Brazil1 and Finian Martin1#.
UCD Schools of 1Biomolecular and Biomedical Science, 2Medicine and Medical
Science, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, 3
Mater Misericordiae University Hospital, Dublin 7, Ireland, 4Division of Nephrology,
Internal Medicine, University of Michigan, Ann Arbor, MI, 5Medizinische Poliklinik,
University of Munich, Germany, 6Division of Nephrology, School of Medicine,
Universidad Austral, Valdivia, Chile.
* These authorsACCEPTED contributed equally to thisMANUSCRIPT study # corresponding author: [email protected]
1 ACCEPTED MANUSCRIPT
Abstract
Diabetic nephropathy is currently the leading cause of end stage renal disease worldwide, and occurs in approximately one third of all diabetic patients. The molecular pathogenesis of diabetic nephropathy has not been fully characterized and novel mediators and drivers of disease are still being described. Previous data from our laboratory has identified the developmentally regulated gene Gremlin as a novel target implicated in diabetic nephropathy in vitro and in vivo. We used bioinformatic analysis to examine whether Gremlin gene sequence and structure could be used to identify other genes implicated in diabetic nephropathy. The Notch ligand Jagged1 and its downstream effector, hairy enhancer of split-1 (Hes1), were identified as genes with significant similarity to Gremlin in terms of promoter structure and predicted micro RNA binding elements. This led us to discover that transforming growth factor- beta (TGFb1), a primary driver of cellular changes in the kidney during nephropathy, increased Gremlin, Jagged1 and Hes1 expression in human kidney epithelial cells.
Elevated levels of Gremlin, Jagged1 and Hes1 were also detected in extracts from renal biopsies from diabetic nephropathy patients, but not in control living donors. In situ hybridization identified specific upregulation and co-expression of Gremlin,
Jagged1 and ACCEPTEDHes1 in the same tubuli of MANUSCRIPT kidneys from diabetic nephropathy patients, but not controls. Finally, Notch pathway gene clustering showed that samples from diabetic nephropathy patients grouped together, distinct from both control living donors and patients with minimal change disease. Together, these data suggest that
Notch pathway gene expression is elevated in diabetic nephropathy, co-incident with
Gremlin, and may contribute to the pathogenesis of this disease.
2 ACCEPTED MANUSCRIPT
Introduction
Diabetic Nephropathy (DN) is the primary cause of end-stage renal disease worldwide
[1]. Both type 1 and type 2 diabetics develop nephropathy. It occurs in 25-40 % of such patients [1]. The initial clinical indicator of DN is microalbuminuria, which reflects functional and potentially reversible abnormalities initiated by glomerular hyperfiltration. Microalbuminuria predicts the development of overt proteinuria in both type 1 and type 2 diabetes patients [2]. Both hyperglycemia and glomerular hypertension are major drivers of DN progression, with current therapies for DN including regulation of blood glucose, angiotensin II receptor antagonists and angiotensin-converting enzyme (ACE) inhibitors which slow, but do not halt the progression to end-stage renal disease once overt nephropathy is established [1]. An underlying genetic susceptibility to DN is suggested by the observation that a cohort of diabetic patients will develop DN despite rigorous hyperglycaemic control.
The pathogenesis of DN is characterized by progressive loss of renal function due to damage to the glomerulus (glomerulosclerosis), and scarring of the kidney tubules due to relentless accumulation and deposition of extracellular matrix (ECM)
(tubulointerstitial fibrosis). Epithelial-mesenchymal transition (EMT) is a process in which renal ACCEPTEDtubular cells lose their epithelial MANUSCRIPT phenotype and acquire characteristic features of mesenchyme, compromising the function of both proximal and distal tubules. There is some disagreement in the literature as to the pathophysiological significance of EMT in diabetic nephropathy in vivo. Those who support a role for
EMT in renal fibrosis in vivo suggest that up to 35 % of disease-related fibroblasts originate from tubular epithelial cells, with in situ fibroblast proliferation and infiltration of circulating fibroblasts also contributing to this process [3, 4]. EMT is therefore considered by some to be a phenotypic conversion fundamentally linked to
3 ACCEPTED MANUSCRIPT
the pathogenesis of renal interstitial fibrosis [5]. Many extrinsic drivers of EMT in kidney have been identified, including transforming growth factor-b (TGFb1), epidermal growth factor (EGF) and advanced glycation end-products (AGEs) [6], [7],
[8]. TGFb1 signals through complexes of heterotrimeric transmembrane type I and type II receptors, activating Smad-2 or -3 to form complexes with Smad4 and trigger transcriptional changes that drive EMT and fibrosis during diabetic nephropathy.
Molecular interventions that act to reduce TGFb1 activity have been shown to be of benefit in renal fibrosis in vivo [9-11]. Treatment of renal epithelial cells with TGFb in culture is sufficient to induce EMT, as characterised by loss of E-cadherin expression and increased vimentin expression [12]. In contrast, proteins such as hepatocyte growth factor (HGF) and bone morphogenic factor-7 (BMP-7) have been shown to counteract EMT induction by TGF-beta in vitro and in vivo [13].
The majority of renal tubules in the adult kidney derive from the metanephric mesenchyme via a process called mesenchymal-epithelial transition (MET). Many genes that play a role in embryogenesis and development have been implicated in diabetic nephropathy. Prominent among these is Gremlin, a member of the noggin/chordin like family of bone morphogenic protein (BMP) antagonists [14]. In vitro, GremlinACCEPTED expression is elevated inMANUSCRIPT kidney mesangial cells treated with high glucose and TGFb1 [15]. Mice lacking Gremlin die shortly after birth due to renal agenesis [16]. Gremlin expression is low in normal, adult kidney but is highly expressed in areas of tubular fibrosis in kidneys from diabetic nephropathy patients
[17]. Increased Gremlin expression during nephropathy fits within the paradigm of aberrant developmental gene expression during disease progression.
We assessed the Gremlin proximal promoter for conserved regulatory elements and identified members of the Notch signalling pathway sharing common regulatory
4 ACCEPTED MANUSCRIPT
elements with Gremlin. We also show that members of the Notch signalling pathway are co-upregulated with Gremlin in an in vitro model of TGF-b induced EMT.
Coordinated increases in Gremlin and Notch family gene expression were also detected in kidney biopsies from diabetic nephropathy patients, with colocalisation of
Gremlin, Jagged1 and Hes1 detected predominantly in the tubular compartments of kidneys from such patients. These data therefore shed new light on the complex alterations in kidney gene expression during diabetic nephropathy.
ACCEPTED MANUSCRIPT
5 ACCEPTED MANUSCRIPT
Material and Methods
Transcription Factor Binding Element Analysis
Experimentally confirmed 5’ capped transcription start sites for human and mouse
Gremlin were determined from the Database of Transcription Start Sites (DBTSS)
(http://dbtss.hgc.jp/) [18] and the 1kb proximal promoters for Gremlin from both species was retrieved from their database. The proximal promoter for rat Gremlin was retrieved from the UCSC Genome Browser (http://genome.ucsc.edu/) [19] using the
Refseq transcription start site. Initial analysis of Gremlin promoter was performed using the sequence alignment programs ClustalW (http://www.ebi.ac.uk/clustalw/)
[20] and Pipmaker (http://pipmaker.bx.psu.edu/pipmaker/) [21] to ascertain sequence conservation. In order to determine if the apparent promoter conservation was due to a confounding influence, such as extraneous open reading frames, the locus was analysed using the UCSC Genome Browser. Having established no confounding influence, the human, mouse and rat 1 kb proximal promoters were analysed for the presence of transcription factor binding site consensus sequences using Matinspector
(http://www.genomatix.de) [22]. In order to reduce the number of false positives, results were filtered for transcription factor sites appearing in all three species.
Clusters of significantlyACCEPTED conserved transcription MANUSCRIPT factor binding sites were chosen to search for promoters with comparable sets of binding sites. Matrices corresponding to the conserved transcription factor binding sites were retrieved from MatBase
(http://www.genomatix.de). Then a library of approximately 12,000 Unigene accession 1 kb promoters was generated using HOMGL (http://homgl.biologie.hu- berlin.de/homgl/) [23]. In order to determine which promoters in this library contained clusters of these motifs, the promoter library was searched with
ClusterBuster (http://zlab.bu.edu/cluster-buster/) [24]. The promoters which were
6 ACCEPTED MANUSCRIPT
identified were further filtered by gene ontology, using the tool eGON
(http://www.genetools.microarray.ntnu.no/egon/index.php) [25], to increase the probability of finding co-regulated genes. This yielded a list of 10 genes, sharing two gene ontology annotations with Gremlin and whose 1 kb proximal promoters contained clusters of transcription factor binding motifs in common with those conserved in the Gremlin promoter.
3’ UTR Conserved Motif Analysis
We used a set of 106 conserved 3’ UTR 8-mer motifs that were identified in a genome-wide search [26]. Many of these conserved sites match known miRNA binding sites. By parsing a table of the genes harbouring these putative miRNA binding sites (Supplementary Materials – [26]), we created a matrix of Refeq Ids and the conserved motifs. To determine if the Gremlin 3’ UTR contained a conserved motif and if any other genes shared such a motif, the matrix was searched for sites matching the Gremlin 3’ UTR and cross-referenced for other genes in whose 3’ UTR they appear. This process was carried out using R and perl scripts.
CpG Island MotifACCEPTED Analysis MANUSCRIPT
There are two CpG islands in the Gremlin promoter. We decided to examine if any other genes contained similar promoter CpG islands containing similar motifs.
Transcription factor binding motifs (1217 motifs) were obtained from TRANSFAC
6.2 Professional [27], Jaspar [28] and from the collection of Xie et al. [26]. Promoter sequences were taken from the 4-way conserved genome sequence (human, mouse, rat and dog) as generated by Xie et al. [26]. The tffind program from the Piptools package [29] was used to generate a frequency matrix of the hits for each of the 1,217
7 ACCEPTED MANUSCRIPT
motifs in each of the 11,241 genes. The cpgplot program from the EMBOSS package
(http://emboss.sourceforge.net/apps/cvs/cpgplot.html) was then used to detect CpG islands in the human promoter sequences. We scanned the conserved regions of the
CpG islands in the Gremlin promoter and identified conserved motifs. We then identified similar conserved motifs in the CpG islands of other genes.
Cell Culture
Human kidney epithelial cells (HK-2) were purchased from the European Collection of Cell Cultures (ECACC). HK-2 cells were cultured at 37 oC in a humidified atmosphere of 95 % air/5 % CO2, and maintained in DMEM-F12 (Sigma) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
10 ng/ml EGF, 36 ng/ml hydrocortisone, 4 pg/ml triiodothyronine and 5 mg/ml insulin-transferrin-selenium (ITS) solution (Sigma). Cells were subcultured using trypsin-EDTA at a ratio of 1:5.
Expression Microarray Analysis
Human kidney proximal tubular epithelial cells (HK-2) were plated in triplicate for stimulation with TGFb1 for 0, 24 or 48 h. This experiment was carried out three times ACCEPTED MANUSCRIPT on different days, with triplicate samples for each time-point being pooled on each occassion, giving a total of 9 samples for Affymetrix expression microarray analysis.
Total RNA was isolated using the Trizol method and purified on Qiagen RNeasy columns. Total RNA (5 mg) was used to produce biotinylated cRNA according to the manufacturer’s instructions (Affymetrix, High Wycombe, UK). Affymetrix test3 arrays were used to confirm the quality of the labelled cRNA before hybridization to the Affymetrix HG U133A 2.0 arrays. Raw data were imported into GeneSpring
(version 5.0, Agilent Technologies) normalized per chip to the 50th percentile and per
8 ACCEPTED MANUSCRIPT
gene to the median. A filtering step was applied to select reliable data and also changing data (determined by two-fold changes in normalized expression intensities between any two time points). The entire data set, which is compliant to the MIAME criteria, is described in Roxburgh et al. (in preparation), and will be deposited at Gene
Expression Omnibus upon publication. The data will be available at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token¼vlatfewwemyceh.
Real-time PCR analysis of HK-2 cells
Real-Time TaqMan PCR was used to quantify relative gene expression levels of
Gremlin, Jagged1 and Hes1 from total RNA extracted from human kidney proximal tubular epithelial (HK-2) cells. Pooled total RNA samples from the Affymetrix DNA microarray experiment were used as templates for real-time PCR validation. The PCR primers and TaqMan probe for Gremlin were: Forward 5’-
GCAAAACCCAGCCGCTTAA-3’, reverse 5’-GGTTGATGATGGTGCGACTGT-
3’, Taqman probe 5’-CAGACCATCCACGAGGAAGGCTGC-3’. The primers and probe for E-cadherin, vimentin, Jagged1 and Hes1 were supplied as a pre-optimised single tube primer/probe Gene Expression Assay (Applied Biosystems). The probes for the targetACCEPTED genes were labelled with theMANUSCRIPT fluorescent dye, FAM on the 5’ end and a non- fluorescent quencher on the 3’ end. 18s rRNA was used as an endogenous control for normalisation of the target genes. 18s primers and probe were supplied as a pre-developed assay reagent (PDAR, Applied Biosystems) labelled with VIC at the
5’ end and TAMRA on the 3’ end. PCR reactions were set up with Taqman Universal
PCR Master Mix from Applied Biosystems. cDNA was amplified on the 7900HT
Sequence Detection System (Applied Biosytems) at default thermal cycling conditions: 2 min at 50 °C, 10 min at 95 °C for enzyme activation and then 40 cycles
9 ACCEPTED MANUSCRIPT
of 15 sec at 95 °C for denaturation and 1 min at 60 °C for annealing and extension.
Results were analysed using the relative standard curve method of analysis/DCt method of analysis.
Clinical Biochemistry
Serum creatinine and proteinuria were analyzed at each clinical center by standard, local techniques. Glomerular filtration rate (GFR) was calculated using the Cockroft-
Gault formula.
Real-time PCR and expression microarray analysis of human renal biopsies
Human renal biopsy specimens were collected in an international multi-centre study, the European Renal cDNA Bank-Kroener-Fresenius biopsy bank (ERCB-KFB, see
(ERCB-KFB, see Lindenmeyer et al., JASN, 2007 for participating centres). Biopsies were obtained from patients after informed consent and with approval of the local human research ethics committees.
Real-time PCR analyses of biopsies from patients with diabetic nephropathy, minimal change disease (MCD) or control living donor (LD) tissue were performed. Following renal biopsy,ACCEPTED the tissue was transferred MANUSCRIPT to RNase inhibitor and micro-dissected into glomerular and tubular fragments. Total RNA was isolated from micro-dissected tubulointerstitial tissue (for details see [30]). Reverse transcription and real-time PCR was performed as reported earlier [30]. Pre-developed TaqMan reagents were used for human Gremlin, Jagged1 and Hes1. Expression of target genes were normalized to three different housekeepers (rRNA, GAPDH and cyclophilin) (Applied Biosystems) giving comparable results. The mRNA expression was analyzed by standard curve quantification. Statistical analysis of the correlation of Gremlin, Jagged1 and Hes1
10 ACCEPTED MANUSCRIPT
was performed by normalization of the expression of each of the genes to GAPDH,
Cyclophilin and rRNA housekeepers separately. We performed Pearson and
Spearman analyses to determine if the expression of the three genes correlated significantly. We also performed Mann-Whitney statistical analysis to determine if the normalized expression of Gremlin, Jagged1 and Hes1 differed significantly between the diabetic group, compared to MCD or LD.
A set of samples from this collection was also analyzed by expression microarray analysis (Affymetrix). A total of 24 kidney biopsies from individual patients were included in this study: 3 pre-transplant kidney biopsies from living donors (LD), 4 cadaveric donors (CD), 4 minimal change disease (MCD) and 13 progressive diabetic nephropathy patients (DN). The three groups (LD, CD and MCD) were used as controls in the experiment (see ref`. 31). The protocols for Affymetrix microarray analysis and clinical data are given at http://diabetes.diabetesjournals.org [31].
Subsequently, the expression of genes of interest (Notch pathway gene members) was visualized using the normalized RMAexpress (http://rmaexpress.bmbolstad.com/) data and an Unsupervised Hierarchical Cluster performed by dChip software [31].
In situ hybridizationACCEPTED MANUSCRIPT Kidney samples were obtained by percutaneous renal biopsy from patients undergoing diagnostic evaluation at the Division of Nephrology, Austral University, Valdivia,
Chile. The samples were studied after obtaining patient consent and the project was approved by the local hospital ethics committee. Renal biopsies from controls or diabetic nephropathy patients diagnosed before specific treatment were studied.
Control human kidney specimens (n = 5) were taken from unaffected kidney portions of tumour nephrectomies.
11 ACCEPTED MANUSCRIPT
In situ hybridization (ISH) was performed as described previously for the TGFb anti- sense probe (R&D Systems, Minneapolis, MN, USA; [32]) and with the following modifications for biotin-labeled human Gremlin (Invitrogen, Carlsbad, CA, USA),
Jagged1 and Hes1 (Sigma) probes. The Gremlin probe was: anti-sense 5’-
CAGGCACTGACTCAGGAAGACA-3´, Jagged1 probe mix was: anti-sense 5’-
CCTGACAGTATTATTGAAAAGGCT-3´ anti-sense 5´-
GTACGGCTGGCAAGGCTTGTACTG-3’ and anti-sense 5’-
CACGCCTGCCTCTCTGATCCCTGT-3’ ; Hes1 probe mix was 5’-
CCTCTCTCCTTGGTCCTGGAACAG-3’ anti-sense 5’-
CTGCGCTGAGCACAGACCCAAGTG-3’. For Gremlin, Jagged1 and Hes1 analysis, pre-treatment with endogenous biotin blocking system (Dako Co,
Carpinteria, CA, USA) was performed prior to proteinase K digestion. The sections were incubated with a pre-hybridization solution (Dako, mRNA ISH Solution) for 60 min at 37 ºC followed by incubation with the antisense probe overnight at 37 ºC. The slides for Gremlin, Jagged1 and Hes1 were washed twice with 2 X SSC, 1 X SSC and
0.5 X SCC for 5 min at 37 ºC. Detection was performed with streptavidin-alkaline phosphatase conjugate (Dako) for 30 min at room temperature, washed 5 min with 1
X TBS. NBTACCEPTED-BCIP enzyme substrate (R&D MANUSCRIPT Systems) was added for 60 min at 37 ºC.
Tissues were then dehydrated in ethanol series and mounted in Canadian balsam
(Polysciences Inc., Warrington, PA, USA).
12 ACCEPTED MANUSCRIPT
Results
Promoter conservation exists between human Gremlin, Jagged1 and Hes1
We initially performed an alignment of human, mouse and rat Gremlin promoter regions. Experimentally confirmed proximal promoters for human and mouse
Gremlin were retrieved from the DBTSS (database of transcriptional start sites, http://dbtss.hgc.jp/). The rat Gremlin proximal promoter was retrieved from the
UCSC Genome Browser (http://genome.ucsc.edu/). The Gremlin 5kb proximal promoter for human, mouse and rat were then aligned using MultiPipMaker
(http://pipmaker.bx.psu.edu/pipmaker/). Conservation was evident up to 2,800bp upstream of the transcription start site and was highest in the 800 bp proximal to the transcription start site (Fig.1a). Due to the high level of conservation, the possibility of a confounding influence such as the presence of another open-reading-frame was investigated using the UCSC Genome Browser. No confounding influence was found, suggesting that the conservation was that of the functional Gremlin promoter. To analyse the potential transcription factors responsible for Gremlin regulation,
Matinspector (http://www.genomatix.de/) to search for conserved transcription factor binding sites. Within the 1 kb region of human, rat and mouse Gremlin promoters, two blocks ofACCEPTED transcription factor binding MANUSCRIPT sites were detected, from -50 to -600 bp and from -600 to -900 bp (Fig. 1b).
From -50 to -600 bp, transcription factor binding sites were highly conserved in all 3 species. In the -600 to -900 bp region, some conservation was still apparent, but the order and position of the sites was less conserved than in the -50 to -600 bp region.
Twenty three conserved transcription factor binding sites were chosen from the -50 to
-600 bp region to search the promoter library for the presence of clusters of such binding elements in other promoters (see Table 1, Supplemental Data). The
13 ACCEPTED MANUSCRIPT
transcription factor binding sites were chosen due to known TGFb regulation or strong involvement in embryogenesis (e.g. Smad, Pax, GATA). ClusterBuster analysis (see Materials and Methods) revealed that genes previously shown to be co- regulated with Gremlin in diabetic nephropathy such as Profilin 1 (13.7) and
CTGF/Cyr61 (12.5) [33] were amongst the highest scoring promoters detected (Fig.
1b). Gremlin (10.4) itself also scored highly in the analysis. When gene ontology information was added to the resulting list, 10 genes shared two ontological traits
(extracellular secreted protein and morphogenesis) with Gremlin. Of those, apart from the Gremlin and CTGF / Cyr61, Inhibin-A and Jagged1 scored most highly in the
ClusterBuster analysis. These data suggest that significant homology and similarity exists between the promoters of Gremlin, CTGF/Cyr61 and Jagged1.
To provide further evidence for potential co-regulation of Gremlin and genes such as
Jagged1, we scanned the identified gene sequences for predicted microRNA (miRNA) binding sites. miRNA analysis using 3’ UTR conserved sequences in [26] indicated that Gremlin had 5 putative miRNA binding sites in its 3’ UTR. Twenty three genes in the database shared one or more of these sites. Using HOMGL
(http://homgl.biologie.hu-berlin.de/homgl/), we then compared the ClusterBuster gene list with the ACCEPTEDmiRNA gene list and found MANUSCRIPT that 4 genes appeared on both lists. These included Gremlin itself, and one other gene which also shared ontological traits with
Gremlin- the Notch ligand Jagged1 (Fig. 2a).
Finally, we identified TFBS motifs in CpG islands in Gremlin spanning the transcription start site (tss) and in the region proximal to the coding sequence, that were conserved in human, mouse, rat and dog. A comparison of these genes containing CpG islands revealed that both Gremlin and Hes1 had a conserved NFkB
14 ACCEPTED MANUSCRIPT
motif in CpG islands near their promoters (Fig. 2b), suggesting the possibility of co- regulation of Notch pathway expressing genes with Gremlin.
Based on the conservation of promoter sequences between Gremlin and Jagged1, together with common predicted microRNA sites and conserved promoter motifs in
Hes1, these data suggest that genes expressing Notch signalling pathway components may be co-regulated with Gremlin. It was therefore of interest to observe if this potential co-regulated expression was associated with renal fibrosis and the pathogenesis of diabetic nephropathy.
TGFb1 stimulates Gremlin, Jagged1 and Hes1 gene expression in renal tubular epithelial cells by microarray analysis
TGFb1 is a major driver of epithelial-mesenchymal transition (EMT) and renal fibrosis both in vitro and in vivo [34] [35]. To evaluate the effect of TGFb1 on kidney cell gene expression, HK-2 tubular epithelial cells were treated with TGFb1 for various times to stimulate EMT-like cellular changes. Induction of EMT was validated by decreased E-cadherin expression (epithelial cell marker) and increased vimentin expression (mesenchymal cell marker, Fig. 3a). RNA was then probed on human HG U133AACCEPTED 2.0 Affymetrix gene MANUSCRIPT arrays, and changes in expression assessed using GeneSpring software. Using a signal-log ratio of 1.5 (representing a 2-fold change in gene expression), expression of 109 genes was upregulated in response to
TGFb1, whereas 97 genes were downregulated in the same experiment (Roxburgh et al., in preparation). Several genes whose altered expression had previously been identified by our group and others in models of EMT were identified, including fibronectin, type 1 collagen alpha 1, type IV collagen alpha 1 and connective tissue
15 ACCEPTED MANUSCRIPT
growth factor (CTGF) suggesting that these epithelial cells had indeed undergone
EMT-like changes (Fig. 3b).
Interestingly, the most highly upregulated gene in response to TGFb1 at both 24 h and
48 h time points was Jagged1, with a 17-fold upregulation at 24 h and an 18-fold upregulation at 48 h detected (Fig. 4). Increased expression of hairy enhancer of split
(Hes-1) was also detected in the microarray experiment, with 3-fold increases at 24 h and 48 h detected (Fig. 4). As previously demonstrated, TGFb1 increased Gremlin expression in kidney epithelial cells (3-fold at 24 hr and 4 fold at 48 h, Fig. 4). To verify these data, real-time TaqMan PCR was performed using oligonucleotides specific for Gremlin, Jagged1 and Hes1. Increases in expression in all three genes at both time points were observed using TaqMan PCR, and the fold-change in expression was similar to that observed by microarray expression analysis (Fig. 4 lower panels). These data suggest that TGFb1, a major pro-fibrotic cytokine, increased the expression of Jagged1 and Hes1, together with Gremlin, in human kidney epithelial cells in vitro.
Expression of Gremlin, Jagged1 and Hes1 is elevated in biopsies from diabetic ACCEPTED MANUSCRIPT nephropathy patients by real-time PCR To examine whether increased expression of Notch signalling pathway genes was a feature of human diabetic nephropathy, samples from human patients were analysed.
The clinical profile of our patient cohort of living donor (LD) cadaveric donor (CD), minimal changes disease (MCD) and diabetes showed significantly reduced glomerular filtration rates (GFR) in diabetic patients versus controls (Diabetes, 36.6 ml/min +/- 14.7, minimal change disease (MCD) 102.25 ml/min +/-24.99, p < 0.05), suggesting stage III to IV chronic kidney disease (CKD). Renal biopsy cores from
16 ACCEPTED MANUSCRIPT
these patient cohorts were micro-dissected, and RNA was extracted from the isolated tubulointerstitial segments. Tubulointerstitial RNA from diabetic patients, transplant donor controls and minimal change disease controls was analysed for the expression of Jagged1, Hes1 and Gremlin using qRT-PCR. Figure 5 shows that, using the Mann-
Whitney-Test to analyze differences, the cohort of diabetic nephropathy patients exhibited a significantly higher expression of Gremlin, Hes1 and Jagged1 compared to control patients (LD) and minimal changes disease (MCD, Fig. 5). Furthermore, the expression of all three genes in the renal tubulointerstitium correlated with each other when normalized to any of 3 housekeeping genes separately (see legend of Fig. 5).
These data suggest that Jagged1 and Hes1 gene expression is upregulated in a coordinated fashion in the tubulointerstitial of kidneys from diabetic nephropathy patients with that of Gremlin.
Increased expression of Jagged1 and Hes1 and Gremlin is detected in the tubular compartment of renal biopsies from diabetic nephropathy patients by in situ hydridisation
To identify the specific region of the nephron where Gremlin, Jagged1 and Hes1 levels were upregulatedACCEPTED in diabetic nephropathy, MANUSCRIPT their expression was studied by in situ hybridization (Fig. 6). No expression of Gremlin, Jagged1 or Hes1 was observed in normal human kidney (Fig. 6, upper panels). In contrast, abundant Gremlin,
Jagged1 and Hes1 mRNA expression was co-expressed in tubular epithelial cells in serial sections of kidney biopsies from patients with diabetic nephropathy (Fig. 6, lower panels). Expression of all three genes appears to localize to the same tubular structures, based on staining of serial sections. These data suggest that upregulation of
17 ACCEPTED MANUSCRIPT
Gremlin, Jagged1 and Hes1 occurs in the tubuloepithelium during the progression of diabetic nephropathy.
Notch-signalling pathway genes are upregulated in biopsies from diabetic nephropathy patients
To broaden our analysis, expression microarray data of tubulointerstitium from patients with established diabetic nephropathy (DN) versus either living donor pre- transplant biopsies (LD) alone or including minimal change disease (MCD) or cadaveric donor (CD) as controls were analysed for the expression levels of all detectable members of the Notch signalling pathway. The clinical profile of these patients was previously published by Schmid and colleagues [31]. Using a cutoff expression value of 5.83 and a p-value < 0.05, ten Notch-pathway related genes were found to be significantly differentially expressed in DN versus LD and MCD.
Included among these were the Notch ligand Jagged1-1, two Notch receptors Notch-2 and Notch-3 and SKI-Interacting Protein (SKIP, Fig, 7). Of these genes, MECT1 and
NOTCH3 were found to be significantly downregulated in the DN group, while genes such as Jagged1, Notch2 and ADAM10 are all upregulated (Fig. 7). Thus, the expression levelsACCEPTED of multiple genes in MANUSCRIPT the Notch signal transduction pathway are altered in diabetic nephropathy.
18 ACCEPTED MANUSCRIPT
Discussion
The data presented in this report explore the parallel potentially coordinated upregulation of Gremlin and Notch family genes in the kidneys of diabetic nephropathy patients. Using a bioinformatics approach, common clusters of transcription factor binding and regulatory elements in the promoters of Gremlin and
Jagged1 (the Notch ligand) were identified. TGFb1, the primary pro-fibrotic cytokine involved in renal fibrosis, increased the expression of Gremlin, Jagged1 and Hes1 (a downstream target of the Notch signalling pathway) within the same time-frame in tubular epithelial cells. Elevations in all three genes were observed in cDNA samples isolated from kidney biopsies from diabetic nephropathy patients, but not controls. In situ hybridization identified the kidney tubules as the main site of Gremlin, Jagged1 and Hes1 upregulation during DN. Finally, changes in expression of other members of the Notch signalling pathway were also detected in renal biopsies from DN patients, suggesting that upregulation of Notch pathway signalling is a feature of diabetic nephropathy.
Bioinformatic analysis of Gremlin genomic sequences from human, mouse and rat revealed an unusually high degree of conservation up to -2800 bp upstream of the predicted transcriptionACCEPTED start site, with particularly MANUSCRIPT strong alignment in the first 800 bp (Fig. 1a). Recent studies suggest that the average sequence identity between orthologous human and mouse promoter regions peaks at approximately 70% at the
TSS [36, 37] and falls rapidly with distance from the TSS. The comparatively high degree of conservation evident in orthologous Gremlin human, mouse and rat promoters suggested that common sequence elements exist and are functionally relevant in the promoters of Gremlin in all three species.
19 ACCEPTED MANUSCRIPT
Consistent with the high degree of conservation in the Gremlin promoter, clusters of transcription factor binding sites common to human, rat and mouse were identified, many of which had previously been implicated in TGFb signalling and embryogenesis (Fig. 1b). These included Smad3 [38], Fast1 [39] and Mitf [40].
These conserved transcription factor binding elements were then used to identify other genes with common promoter regulatory elements. This approach identified the previously implicated TGFb1 co-regulated gene CTGF, as well as Gremlin itself (Fig.
1b). Also present in this group was Jagged1, the ligand for the Notch receptor which regulates multiple developmental processes [41]. Mutations in Jagged1 can lead to the genetic disorder Alagille syndrome [42], which results in multi-organ defects, including, but not limited to cardiac, ocular and facial [43]. A similar approach was taken by Kielbasa et al. [44], who described a method for predicting muscle-specific gene targets for a set of transcription factors also using a strategy centred on analysis within Cluster-Buster.
The presence of common motifs in CpG islands in Gremlin and Hes1 (a downstream target of Jagged1/Notch signalling) genes, as well as micro RNA binding sites in the
3’ UTR of Gremlin and Jagged1 genes further support our suggestions that common regulatory strategiesACCEPTED exist for expression MANUSCRIPT of Gremlin and genes of the Notch signalling pathway. Both Gremlin and Jagged1 control developmental processes in many species
[16, 45-47]. Gremlin is a BMP antagonist whose temporal and spatial expression is crucial to normal development [16]. Mice lacking Gremlin exhibit limb deformities in both fore and hind-limb [16]. Of relevance to our study, mice lacking Gremlin die shortly after birth due to renal agenesis [16], suggesting an important role for Gremlin in kidney development. Jagged1 mutations cause Alagille syndrome in humans, an autosomal dominant condition affecting the liver, kidneys, heart and craniofacial
20 ACCEPTED MANUSCRIPT
structures [48]. To date, common mechanisms of regulation for Gremlin and Jagged1 have not been described, although coordinated expression of both genes may be required for correct sonic hedgehog signalling during epithelial-mesenchymal signalling in mouse limb bud development [49].
TGFb1 is a key pathogenic driver of renal fibrosis in diabetic nephropathy and other forms of kidney disease [50]. TGFb1 stimulates increases in expression of genes such as fibronectin, CTGF and Gremlin in models of glucose-induced damage in kidney cells [15]. Cells treated with TGFb1 underwent EMT-like changes, as confirmed by decreased E-cadherin levels and increased vimentin expression (Fig. 3a). Treatment of renal epithelial cells with TGFb1 is known to induce EMT in epithelial cells [13].
Several genes that are also charactieristic of TGFb1-induced fibrosis were also increased, including fibronectin, collagen and CTGF (Fig. 3b). TGFb1 increased the expression of Gremlin, as well as Jagged1 and Hes1 in human proximal epithelial cells (HK-2) in a cell culture model of epithelial-mesenchymal transition (EMT, Fig.
4). In agreement with our identification of common regulatory elements within the
Gremlin and Jagged1 promoters, our data suggested that signal transduction cascades triggered by TGFb1 activated the expression of Gremlin and Jagged1, as well as Hes1 ACCEPTED MANUSCRIPT in tubular epithelial cells. Morrissey and colleagues have also observed TGFb1- mediated Jagged1 upregulation in human kidney cells [51]. These authors also identified the kidney tubules as the primary site of Jagged1 upregulation in a mouse model of acute renal fibrosis [51]. Other data suggests that TGFb-induced EMT in human keratinocytes is associated with the expression of the hairy enhancer of split- like genes in the Notch signalling pathway [12]. Functional inactivation of the Notch ligand Jagged1 or Notch has also been shown to inhibit TGFb1 induced EMT [52].
Notch signalling induced by TGFb has been shown to occur in a biphasic manner
21 ACCEPTED MANUSCRIPT
[52]. At the onset of EMT a subset of Notch target genes, together with its ligand
Jagged1 are induced by TGFb1, Smad3-dependent, and Notch independent. After prolonged TGFb1 exposure, a second, sustained wave of Notch signalling occurs through TGFb-induced synthesis of Jagged1, Notch dependent [52]. Together, these data suggest that TGFb1 mediated increases in Notch signalling may act to sustain or amplify its pro-fibrotic effects in kidney cells.
Based on bioinformatic and in vitro data, we hypothesised that coordinated upregulation of Gremlin with members of the Notch signalling pathway such as
Jagged1 and Hes1 is a feature of renal fibrosis. Our diabetic patient cohort displayed a significantly decreased GFR resulting from DN. The scatter in GFR observed in the diabetic patient group is indicative of a heterogeneity in renal function, with values in these patients ranging from 60 ml/min down to 6 ml/min. Thus, the majority of these patients can be classified as either moderate or severe CKD as a result of DN. Levels of all three gene transcripts of interest were elevated in biopsies from diabetic nephropathy patients compared to normal living donor or minimal change disease controls (Fig. 5). Further analysis revealed that the upregulation of all three genes correlated with each other in a statistically significant manner, when compared to any of three housekeepiACCEPTEDng genes. Our correlation MANUSCRIPT analysis highlights that Gremlin,
Jagged1 and Hes1 follow a shared pattern of upregulation in the kidney tubules during diabetic nephropathy. Supporting this conclusion, we observed significant staining of
Gremlin, Jagged1 and Hes1 in the same kidney tubules in diabetic nephropathy, but not in control sections (Fig. 6). Weaker staining for all three genes was observed in glomeruli. Previous reports have identified Gremlin upregulation in the tubular compartment of diabetic nephropathy kidneys [17]. Gremlin mRNA levels correlated well with renal dysfunction in these patients [17]. Similar to Dolan et al. (2005),
22 ACCEPTED MANUSCRIPT
Gremlin upregulation was predominantly detected in the tubulointerstitium, with lower levels evident in the glomerulus. These data suggest that Gremlin, and indeed
Notch family signalling may play a more significant role in tubulointerstitial fibrosis than in glomerulosclerosis during DN. To our knowledge, our data is the first to report increased expression of Notch family genes such as Jagged1 and Hes1 in the kidneys of diabetic nephropathy patients. Furthermore, the strong correlation between Gremlin and Jagged1/Hes1 expression suggests that drivers of renal fibrosis such as TGFb1 may be triggering coordinated waves of such gene expression that contribute to the pathogenesis of renal disease. Based on the tight co-regulation of Gremlin with two genes of the Notch signalling pathway (Jagged1 and Hes1), we then identified other genes in the Notch pathway whose expression was also elevated in kidney biopsies from DN patients compared to controls (Fig. 7). Genes encoding the Notch receptors,
ADAM-10 (a metalloproteinase essential for Notch signalling [53]) and Ski- interacting protein (SKIP, a co-activator of transcription that binds to the activated intracellular portion of the Notch receptor [54]) were all highly expressed in biopsies from human DN patients compared to controls (Fig. 7). These data fit within the paradigm of the re-emergence of developmental gene expression in the context of diabetic nephropathy,ACCEPTED where developmental MANUSCRIPT gene expression may be part of an inappropriate repair mechanism to reverse the progression of renal fibrosis.
Our data describe a novel link between Gremlin upregulation and increased Notch pathway signalling downstream of TGFb1 in diabetic nephropathy. Further experiments are required to determine whether increased Notch signalling acts to amplify or prolong TGFb1 signalling in the diabetic kidney and what is the precise role of Gremlin in this paradigm. Elucidation of these cellular mechanisms will allow
23 ACCEPTED MANUSCRIPT
potentially novel interventions that aim to delay or prevent the onset of renal fibrosis in diabetic nephropathy.
ACCEPTED MANUSCRIPT
24 ACCEPTED MANUSCRIPT
Acknowledgments
SR is supported by a Health Research Board Ireland Clinical Research Fellowship.
Work in DPB and FM laboratories is supported by Science Foundation Ireland. CDC was supported by the Else-Kroener-Fresenius-Foundation. The members of the
European Renal cDNA Bank-Kroener-Fresenius-Biopsy Bank are listed in reference
29 (Lindenmeyer-MT, JASN, 2007). We thank Dr. Yvonne O’ Meara (MMUH) for support and guidance. The technical excellence of Mrs. Catherine Moss and Ms
Allison Murphy (UCD Conway Institute) are gratefully acknowledged. We thank Ms.
Carolina Lavoz, Universidad Austral, Valdivia, Chile for expert assistance with in situ hybridization, and are indebted to Dr. Almut Nitsche and Dr. Bodo Brunner (Sanofi- aventis Deutschland GmbH) for DNA Chip hybridization and delivery of the hybridization dataset.
ACCEPTED MANUSCRIPT
25 ACCEPTED MANUSCRIPT
Figure Legends
Figure 1. Conservation of clusters of transcription factor binding sites in the
Gremlin proximal promoter and their occurrence in other promoters. (A)
Combined dot-plots (upper panel) and pip-plots (lower panel) for the 5 kb proximal promoters of human Gremlin versus mouse Gremlin and human Gremlin versus rat
Gremlin respectively. The human proximal promoter sequence is represented by the horizontal axis in all cases. The dot-plots represent each of the gap-free segments of alignment as a diagonal line indicating position in both the human and mouse sequences and the human and rat sequences. The pip-plots depict each one of these segments of alignment as a horizontal line, the left-to-right position of which is determined by the human coordinates and the vertical placement of which indicates the percent identity of the mouse or rat sequence. In both comparisons regions of sequence identity extend up to 2.8 kb upstream of the transcription start site. With the exception of an apparent deletion in the mouse genome corresponding to -700 to -
1200 bp in human, the sections of gap-free alignments are almost uninterrupted. (B)
Matinspector analysis of human, mouse and rat Gremlin 1 kb proximal promoters (-1 to -400 bp shown). Transcription factor matrices common to all 3 species are shown. Each colouredACCEPTED tab represents an individual MANUSCRIPT binding site identified by Matinspector, [sites are identified in the legend to its right]. The lower panel shows the
ClusterBuster score output for genes identified as having clusters of the transcription factors found conserved in the Gremlin promoter. Shown here are those genes whose score was higher than the 7.0 cut-off and also shared gene ontology with Gremlin.
Highlighted is the Jagged1 1 result, indicating its score of 8.27, the position of the cluster within the promoter region, and to the right a graphical representation of the
26 ACCEPTED MANUSCRIPT
cluster. Once again the coloured tabs represent individual transcription factor matrix sites, and the colours correspond to the matrices above.
Figure 2. Gremlin shares regulatory elements with Jagged1 and Hes1 (A) Using conserved 3’ untranslated (UTR) motif data [26], we identified 5 potential miRNA binding sites in the Gremlin 3’ UTR. Further analysis revealed 23 genes (Table 2,
Supplemental data) that shared one or more of these miRNA target sites. Of these the
Notch ligand Jagged1 shared a TGTGAATA motif in its 3’ UTR with Gremlin. (B)
The Gremlin proximal promoter contains two CpG islands. Within those we found 6 conserved motifs. Of the 6, 5 of them are NFKappa B related, including MA0105
(Jaspar accession) p50 subunit of NFKappaB. We searched for Notch pathway members sharing a similar motif in its CpG island with Gremlin. We found that Hes1 also contain a CpG island in its proximal promoter, and similarily contains a MA0105 motif.
Figure 3. TGFb1 induces gene expression-like changes in human kidney epithelial cells consistent with EMT. Human proximal tubule kidney epithelial cells
(HK-2) were treated for 0, 24 or 48 h with 10 ng/ml TGFb1. Total RNA was extracted and processedACCEPTED for quantitative TaqMan MANUSCRIPTPCR and Affymetrix microarray analysis as described. (A) Specific TaqMan probes for E-cadherin and vimentin were used to amplify individual RNA transcripts. Fluoresence intensities were normalised to 18s levels for each gene. Mean fold-change in expression for each experiment (in triplicate) were calculated and plotted versus TGFb1 exposure time (h). Error bars represent standard error of the mean (SEM). Statistical significance was calculated using two-tailed t-tests. * p<0.02, ** p<0.05, *** p<0.0001, **** p<0.00005. (B)
Total RNA was analysed on HG U133A 2.0 Affymetrix chips as described in
27 ACCEPTED MANUSCRIPT
Materials and Methods. Fold change in expression of fibronectin, collagen, Gremlin and CTGF at 24 and 48 h compared to control are indicated.
Figure 4. TGFb1 induces Gremlin, Jagged1 and Hes1 expression in human kidney epithelial cells in culture. Human proximal tubule kidney epithelial cells
(HK-2) were treated for 0, 24 or 48 h with 10 ng/ml TGFb1. Total RNA was extracted and processed for Affymetrix microarray analysis as described in Materials and
Methods. (A) Changes in gene expression were determined using Affymetrix
GeneSpring® analysis software. Each time-point is the average of three independent experiments carried out on separate days. Fold change in expression of Gremlin,
Jagged1 and Hes1 are plotted versus duration of TGFb1 treatment (h). (B)
Quantitative TaqMan PCR was carried out on the total RNA samples used in the
Affymetrix experiment above. Specific TaqMan probes for Gremlin, Jagged1 and
Hes1 were used to amplify individual RNA transcripts. Fluorescence intensities were normalised to 18s RNA levels for each gene. Mean fold change in expression for each experiment (in triplicate) were calculated and plotted versus duration of TGFb1 treatment (h). Error bars represent standard error of the mean (SEM). Statistical significance ACCEPTEDwas calculated using two -MANUSCRIPTtailed t-tests. * p<0.01, ** p<0.05, *** p<
0.005, **** p< 0.00005, ***** p<0.000001.
Figure 5. Increased expression of Gremlin, Jagged1 and Hes1 mRNA was detected in biopsies from diabetic nephropathy patients, by RT-PCR. Real-time
Taqman PCR was performed on RNA extracted from renal biopsies from control living donor (LD, n=10), minimal change disease (MCD, n=5) or diabetic nephropathy (diabetes, n=18) as described in Materials and Methods. Shown is the
28 ACCEPTED MANUSCRIPT
expression level in arbitrary units for Gremlin, Jagged1 and Hes1 normalized to the housekeeper GAPDH. Using Mann-Whitney non-parametric tests we found that the diabetic group shows significantly higher expression of Gremlin (p = 0.006), Jagged1
(p = 0.001) and Hes1 (p = 0.011) compared to LD and MCD. This was true for all housekeepers used. Both latter groups do not show a significant difference in expression levels. Using Pearson (numeric) and Spearman (rank) tests we analyzed the expression levels of the 3 genes for statistical correlation, normalized to each housekeeper separately. The expression levels of the 3 genes were found to correlate significantly. This was true for each housekeeper and for both statistical tests. In the
Pearson/Parametric tests Gremlin and Jagged1 had correlation coefficients of 0.627
(rRNA), 1.000 (GAPDH) and 0.756 (Cyclo), in the non-parametric/Spearman-Rho tests the coefficients were 0.530 (rRNA), 0.876 (GAPDH) and 0.674 (Cyclo). For
Gremlin and Hes1 the Pearson coefficients were found to be 0.519 (rRNA), 0.999
(GAPDH) and 0.544 (Cyclo), the Spearman-Rho coefficients were 0.346 (rRNA)
(0.05 level significance), 0.809 (GAPDH) and 0.527 (Cyclo). In all cases, unless specified, p = 0.01.
Figure 6. Gremlin,ACCEPTED Jagged1 and Hes1 MANUSCRIPTexpression co-localizes to tubular epithelial cells in serial kidney sections of DN patients. In situ hybridization of renal biopsies from control (upper panel) and diabetic nephropathy (lower panel) patients were performed as described in Materials and Methods. Serial sections of 4 µm were stained for Gremlin (left panel), Jagged1 (middle panel) or Hes1 mRNA (right panel).
Glomeruli (*) and tubules (arrows) are indicated.
29 ACCEPTED MANUSCRIPT
Figure 7. Key genes of the Notch signalling pathway are upregulated in Diabetic
Nephropathy. Hierarchical cluster analysis of gene expression profiles from DN renal biopsies and different ‘controls’. Tubulointerstitial compartments of renal biopsies from patients with DN and MCD, as well as pre-transplant biopsies from related LD and CD kidneys, were analyzed. Gene expression profiles were determined using Affymetrix oligonucleotide arrays HG-U133A. Transcript abundance is displayed on a red-green color scale, with red expression above and green below the median. The cluster dendrogram sorts the patients with the most similar gene expression profiles together with the shortest branches. Hierarchical clustering showed a clear distinction between the DN patients and the LD/MCD/CD patients, with CD4 being the one exception, clustering within the DN group. The above cluster shows non-redundant genes expressed higher than the cutoff (expression value = 5.83) that are significantly differentially regulated (p < 0.05). Included in this cluster are genes that function at key points in the Notch pathway: ligand (Jagged1), receptor (Notch2 & Notch3), receptor cleavage (ADAM10), transcriptional activators
(RBPSUH, SKIP), notch ligand activators (MIB1), notch repressor (NLE1) as well as other genes shown to interfere with Notch signaling (APP, MECT1). ACCEPTED MANUSCRIPT
30 ACCEPTED MANUSCRIPT
References
[1] E. Ritz, S.R. Orth, Nephropathy in patients with type 2 diabetes mellitus, N
Engl J Med 341 (1999) 1127-1133.
[2] S.G. Adler, S.W. Kang, S. Feld, D.R. Cha, L. Barba, L. Striker, G. Striker,
B.L. Riser, J. LaPage, C.C. Nast, Can glomerular mRNAs in human type 1
diabetes be used to predict transition from normoalbuminuria to
microalbuminuria?, Am J Kidney Dis 40 (2002) 184-188.
[3] M. Iwano, D. Plieth, T.M. Danoff, C. Xue, H. Okada, E.G. Neilson, Evidence
that fibroblasts derive from epithelium during tissue fibrosis, The Journal of
clinical investigation 110 (2002) 341-350.
[4] R. Kalluri, E.G. Neilson, Epithelial-mesenchymal transition and its
implications for fibrosis, The Journal of clinical investigation 112 (2003)
1776-1784.
[5] Y. Liu, Epithelial to mesenchymal transition in renal fibrogenesis: pathologic
significance, molecular mechanism, and therapeutic intervention, J Am Soc
Nephrol 15 (2004) 1-12. [6] J.M. ACCEPTEDFan, Y.Y. Ng, P.A. Hill, MANUSCRIPTD.J. Nikolic-Paterson, W. Mu, R.C. Atkins, H.Y. Lan, Transforming growth factor-beta regulates tubular epithelial-
myofibroblast transdifferentiation in vitro, Kidney international 56 (1999)
1455-1467.
[7] H. Okada, T.M. Danoff, R. Kalluri, E.G. Neilson, Early role of Fsp1 in
epithelial-mesenchymal transformation, The American journal of physiology
273 (1997) F563-574.
31 ACCEPTED MANUSCRIPT
[8] M.D. Oldfield, L.A. Bach, J.M. Forbes, D. Nikolic-Paterson, A. McRobert, V.
Thallas, R.C. Atkins, T. Osicka, G. Jerums, M.E. Cooper, Advanced glycation
end products cause epithelial-myofibroblast transdifferentiation via the
receptor for advanced glycation end products (RAGE), The Journal of clinical
investigation 108 (2001) 1853-1863.
[9] W.A. Border, N.A. Noble, T. Yamamoto, J.R. Harper, Y. Yamaguchi, M.D.
Pierschbacher, E. Ruoslahti, Natural inhibitor of transforming growth factor-
beta protects against scarring in experimental kidney disease, Nature 360
(1992) 361-364.
[10] Y. Isaka, D.K. Brees, K. Ikegaya, Y. Kaneda, E. Imai, N.A. Noble, W.A.
Border, Gene therapy by skeletal muscle expression of decorin prevents
fibrotic disease in rat kidney, Nature medicine 2 (1996) 418-423.
[11] H. Kasuga, Y. Ito, S. Sakamoto, H. Kawachi, F. Shimizu, Y. Yuzawa, S.
Matsuo, Effects of anti-TGF-beta type II receptor antibody on experimental
glomerulonephritis, Kidney international 60 (2001) 1745-1755.
[12] J. Zavadil, M. Bitzer, D. Liang, Y.C. Yang, A. Massimi, S. Kneitz, E. Piek,
E.P. Bottinger, Genetic programs of epithelial cell plasticity directed by transformingACCEPTED growth factor-beta, MANUSCRIPT Proceedings of the National Academy of Sciences of the United States of America 98 (2001) 6686-6691.
[13] M. Zeisberg, J. Hanai, H. Sugimoto, T. Mammoto, D. Charytan, F. Strutz, R.
Kalluri, BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal
transition and reverses chronic renal injury, Nature medicine 9 (2003) 964-
968.
[14] R. Merino, J. Rodriguez-Leon, D. Macias, Y. Ganan, A.N. Economides, J.M.
Hurle, The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and
32 ACCEPTED MANUSCRIPT
programmed cell death in the developing limb, Development (Cambridge,
England) 126 (1999) 5515-5522.
[15] R. McMahon, M. Murphy, M. Clarkson, M. Taal, H.S. Mackenzie, C. Godson,
F. Martin, H.R. Brady, IHG-2, a mesangial cell gene induced by high glucose,
is human gremlin. Regulation by extracellular glucose concentration, cyclic
mechanical strain, and transforming growth factor-beta1, The Journal of
biological chemistry 275 (2000) 9901-9904.
[16] M.K. Khokha, D. Hsu, L.J. Brunet, M.S. Dionne, R.M. Harland, Gremlin is
the BMP antagonist required for maintenance of Shh and Fgf signals during
limb patterning, Nature genetics 34 (2003) 303-307.
[17] V. Dolan, M. Murphy, D. Sadlier, D. Lappin, P. Doran, C. Godson, F. Martin,
Y. O'Meara, H. Schmid, A. Henger, M. Kretzler, A. Droguett, S. Mezzano,
H.R. Brady, Expression of gremlin, a bone morphogenetic protein antagonist,
in human diabetic nephropathy, Am J Kidney Dis 45 (2005) 1034-1039.
[18] Y. Suzuki, R. Yamashita, K. Nakai, S. Sugano, DBTSS: DataBase of human
Transcriptional Start Sites and full-length cDNAs, Nucleic acids research 30
(2002) 328-331. [19] W.J. Kent,ACCEPTED C.W. Sugnet, T.S. Furey, MANUSCRIPT K.M. Roskin, T.H. Pringle, A.M. Zahler, D. Haussler, The human genome browser at UCSC, Genome research 12
(2002) 996-1006.
[20] J.D. Thompson, D.G. Higgins, T.J. Gibson, CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through sequence
weighting, position-specific gap penalties and weight matrix choice, Nucleic
acids research 22 (1994) 4673-4680.
33 ACCEPTED MANUSCRIPT
[21] S. Schwartz, Z. Zhang, K.A. Frazer, A. Smit, C. Riemer, J. Bouck, R. Gibbs,
R. Hardison, W. Miller, PipMaker--a web server for aligning two genomic
DNA sequences, Genome research 10 (2000) 577-586.
[22] K. Quandt, K. Frech, H. Karas, E. Wingender, T. Werner, MatInd and
MatInspector: new fast and versatile tools for detection of consensus matches
in nucleotide sequence data, Nucleic acids research 23 (1995) 4878-4884.
[23] N. Bluthgen, S.M. Kielbasa, B. Cajavec, H. Herzel, HOMGL-comparing
genelists across species and with different accession numbers, Bioinformatics
(Oxford, England) 20 (2004) 125-126.
[24] M.C. Frith, M.C. Li, Z. Weng, Cluster-Buster: Finding dense clusters of
motifs in DNA sequences, Nucleic acids research 31 (2003) 3666-3668.
[25] V. Beisvag, F.K. Junge, H. Bergum, L. Jolsum, S. Lydersen, C.C. Gunther, H.
Ramampiaro, M. Langaas, A.K. Sandvik, A. Laegreid, GeneTools--
application for functional annotation and statistical hypothesis testing, BMC
bioinformatics 7 (2006) 470.
[26] X. Xie, J. Lu, E.J. Kulbokas, T.R. Golub, V. Mootha, K. Lindblad-Toh, E.S.
Lander, M. Kellis, Systematic discovery of regulatory motifs in human promotersACCEPTED and 3' UTRs by comparison MANUSCRIPT of several mammals, Nature 434 (2005) 338-345.
[27] E. Wingender, P. Dietze, H. Karas, R. Knuppel, TRANSFAC: a database on
transcription factors and their DNA binding sites, Nucleic acids research 24
(1996) 238-241.
[28] A. Sandelin, W. Alkema, P. Engstrom, W.W. Wasserman, B. Lenhard,
JASPAR: an open-access database for eukaryotic transcription factor binding
profiles, Nucleic acids research 32 (2004) D91-94.
34 ACCEPTED MANUSCRIPT
[29] S. Schwartz, L. Elnitski, M. Li, M. Weirauch, C. Riemer, A. Smit, E.D. Green,
R.C. Hardison, W. Miller, MultiPipMaker and supporting tools: Alignments
and analysis of multiple genomic DNA sequences, Nucleic acids research 31
(2003) 3518-3524.
[30] C.D. Cohen, K. Frach, D. Schlondorff, M. Kretzler, Quantitative gene
expression analysis in renal biopsies: a novel protocol for a high-throughput
multicenter application, Kidney Int 61 (2002) 133-140.
[31] H. Schmid, A. Boucherot, Y. Yasuda, A. Henger, B. Brunner, F. Eichinger, A.
Nitsche, E. Kiss, M. Bleich, H.J. Grone, P.J. Nelson, D. Schlondorff, C.D.
Cohen, M. Kretzler, Modular activation of nuclear factor-kappaB
transcriptional programs in human diabetic nephropathy, Diabetes 55 (2006)
2993-3003.
[32] S.A. Mezzano, M.A. Droguett, M.E. Burgos, L.G. Ardiles, C.A. Aros, I.
Caorsi, J. Egido, Overexpression of chemokines, fibrogenic cytokines, and
myofibroblasts in human membranous nephropathy, Kidney international 57
(2000) 147-158.
[33] M. Murphy, C. Godson, S. Cannon, S. Kato, H.S. Mackenzie, F. Martin, H.R. Brady,ACCEPTED Suppression subtractive hybridizationMANUSCRIPT identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in
human mesangial cells, The Journal of biological chemistry 274 (1999) 5830-
5834.
[34] J.B. Kopp, V.M. Factor, M. Mozes, P. Nagy, N. Sanderson, E.P. Bottinger,
P.E. Klotman, S.S. Thorgeirsson, Transgenic mice with increased plasma
levels of TGF-beta 1 develop progressive renal disease, Laboratory
35 ACCEPTED MANUSCRIPT
investigation; a journal of technical methods and pathology 74 (1996) 991-
1003.
[35] N.A. Bhowmick, M. Ghiassi, A. Bakin, M. Aakre, C.A. Lundquist, M.E.
Engel, C.L. Arteaga, H.L. Moses, Transforming growth factor-beta1 mediates
epithelial to mesenchymal transdifferentiation through a RhoA-dependent
mechanism, Molecular biology of the cell 12 (2001) 27-36.
[36] V.X. Jin, G.A. Singer, F.J. Agosto-Perez, S. Liyanarachchi, R.V. Davuluri,
Genome-wide analysis of core promoter elements from conserved human and
mouse orthologous pairs, BMC bioinformatics 7 (2006) 114.
[37] Y. Suzuki, R. Yamashita, M. Shirota, Y. Sakakibara, J. Chiba, J. Mizushima-
Sugano, K. Nakai, S. Sugano, Sequence comparison of human and mouse
genes reveals a homologous block structure in the promoter regions, Genome
research 14 (2004) 1711-1718.
[38] A. Nakao, T. Imamura, S. Souchelnytskyi, M. Kawabata, A. Ishisaki, E. Oeda,
K. Tamaki, J. Hanai, C.H. Heldin, K. Miyazono, P. ten Dijke, TGF-beta
receptor-mediated signalling through Smad2, Smad3 and Smad4, The EMBO
journal 16 (1997) 5353-5362. [39] H.I. Sirotkin,ACCEPTED M.A. Gates, P.D. MANUSCRIPT Kelly, A.F. Schier, W.S. Talbot, Fast1 is required for the development of dorsal axial structures in zebrafish, Curr Biol
10 (2000) 1051-1054.
[40] M. Mochii, Y. Mazaki, N. Mizuno, H. Hayashi, G. Eguchi, Role of Mitf in
differentiation and transdifferentiation of chicken pigmented epithelial cell,
Developmental biology 193 (1998) 47-62.
[41] S. Artavanis-Tsakonas, K. Matsuno, M.E. Fortini, Notch signaling, Science
(New York, N.Y 268 (1995) 225-232.
36 ACCEPTED MANUSCRIPT
[42] K.M. Loomes, L.A. Underkoffler, J. Morabito, S. Gottlieb, D.A. Piccoli, N.B.
Spinner, H.S. Baldwin, R.J. Oakey, The expression of Jagged1 in the
developing mammalian heart correlates with cardiovascular disease in Alagille
syndrome, Human molecular genetics 8 (1999) 2443-2449.
[43] D. Alagille, M. Odievre, M. Gautier, J.P. Dommergues, Hepatic ductular
hypoplasia associated with characteristic facies, vertebral malformations,
retarded physical, mental, and sexual development, and cardiac murmur, The
Journal of pediatrics 86 (1975) 63-71.
[44] S.M. Kielbasa, N. Bluthgen, C. Sers, R. Schafer, H. Herzel, Prediction of cis-
regulatory elements of coregulated genes, Genome informatics 15 (2004) 117-
124.
[45] A. Zuniga, A.P. Haramis, A.P. McMahon, R. Zeller, Signal relay by BMP
antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds,
Nature 401 (1999) 598-602.
[46] S.E. Bell, A. Mavila, R. Salazar, K.J. Bayless, S. Kanagala, S.A. Maxwell,
G.E. Davis, Differential gene expression during capillary morphogenesis in
3D collagen matrices: regulated expression of genes involved in basement membraneACCEPTED matrix assembly, cell MANUSCRIPTcycle progression, cellular differentiation and G-protein signaling, Journal of cell science 114 (2001) 2755-2773.
[47] H. Li, B. Yu, Y. Zhang, Z. Pan, W. Xu, H. Li, Jagged1 protein enhances the
differentiation of mesenchymal stem cells into cardiomyocytes, Biochemical
and biophysical research communications 341 (2006) 320-325.
[48] M. Weller, N. Krautler, N. Mantei, U. Suter, V. Taylor, Jagged1 ablation
results in cerebellar granule cell migration defects and depletion of Bergmann
glia, Developmental neuroscience 28 (2006) 70-80.
37 ACCEPTED MANUSCRIPT
[49] L. Panman, A. Galli, N. Lagarde, O. Michos, G. Soete, A. Zuniga, R. Zeller,
Differential regulation of gene expression in the digit forming area of the
mouse limb bud by SHH and gremlin 1/FGF-mediated epithelial-
mesenchymal signalling, Development (Cambridge, England) 133 (2006)
3419-3428.
[50] E.P. Bottinger, M. Bitzer, TGF-beta signaling in renal disease, J Am Soc
Nephrol 13 (2002) 2600-2610.
[51] J. Morrissey, G. Guo, K. Moridaira, M. Fitzgerald, R. McCracken, T. Tolley,
S. Klahr, Transforming growth factor-beta induces renal epithelial jagged-1
expression in fibrotic disease, J Am Soc Nephrol 13 (2002) 1499-1508.
[52] J. Zavadil, L. Cermak, N. Soto-Nieves, E.P. Bottinger, Integration of TGF-
beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal
transition, The EMBO journal 23 (2004) 1155-1165.
[53] D. Hartmann, B. de Strooper, L. Serneels, K. Craessaerts, A. Herreman, W.
Annaert, L. Umans, T. Lubke, A. Lena Illert, K. von Figura, P. Saftig, The
disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not
for alpha-secretase activity in fibroblasts, Human molecular genetics 11 (2002)ACCEPTED 2615-2624. MANUSCRIPT [54] S. Zhou, M. Fujimuro, J.J. Hsieh, L. Chen, A. Miyamoto, G. Weinmaster, S.D.
Hayward, SKIP, a CBF1-associated protein, interacts with the ankyrin repeat
domain of NotchIC To facilitate NotchIC function, Molecular and cellular
biology 20 (2000) 2400-2410.
38 ACCEPTED MANUSCRIPT
Figure 1 A.
B.
ACCEPTED MANUSCRIPT
39 ACCEPTED MANUSCRIPT
Figure 2a
ACCEPTED MANUSCRIPT
40 ACCEPTED MANUSCRIPT
Figure 2b
ACCEPTED MANUSCRIPT
41 ACCEPTED MANUSCRIPT
Figure 3a
E-cadherin Vimentin 1.4 2.5
1.2 **** * *** 2 ** 1
0.8 1.5
0.6 1 0.4 0.5 0.2 Fold change in expression Fold change in expression
0 0 0hr 24hr 48hr 0hr 24hr 48hr
ACCEPTED MANUSCRIPT
42 ACCEPTED MANUSCRIPT
Figure 3b
Gene name Accession Fold change Fold change number 24 hr 48hr Fibronectin 1 NM_212482 2.64 6.68
Type I collagen, NM_000088 1.91 2.14 alpha 1 Type IV collagen, NM_001845 1.93 1.91 alpha 1 Gremlin NM_013372 3.21 3.98
CTGF NM_001901 1.95 1.8
ACCEPTED MANUSCRIPT
43 ACCEPTED MANUSCRIPT
Figure 4
Hes1 Gremlin Jagged1 5 4 20 4 3 15 3 2 10 2
1 1 5 Fold change in inte n sity Fold c hang e in int ensity Fold change in intensity 0 0 0 0 24 48 0 24 48 0 24 48 time (h) time (h) time (h) Gremlin Jagged1 Hes1 5 20 6 *** ***** 4 5 15 **** ** 4 3 * 10 3 2 2 5 1 1 Fold change in expression Fold change in expression 0 0 Fold change in exp ression 0 0hr 24hr 48hr 0 24hr 48hr 0 24hr 48hr
ACCEPTED MANUSCRIPT
44 ACCEPTED MANUSCRIPT
Figure 5
Gremlin Jagged1 10 10
1 1
0.1 0.1
0.01 0.01 (arbitrary units) (arbitrary units) mRNA copy number mRNA copy number 0.001 0.001 Diabetes LD MCD Diabetes LD MCD
Hes1 10
1
0.1
0.01 (arbitrary units) mRNA copy number
0.001 Diabetes LD MCD
ACCEPTED MANUSCRIPT
45 ACCEPTED MANUSCRIPT
Figure 6
Control
* * Diabetes *
Gremlin Jagged1 Hes1
ACCEPTED MANUSCRIPT
46 ACCEPTED MANUSCRIPT
Figure 7
ACCEPTED MANUSCRIPT
47